← Search & browse all drugs

lotilaner

S01AX25

Forms & Strengths

Chewable tablets 20 mg (1 mg/kg) and 56 mg (2.8 mg/kg) for dogs
Flavored for oral administration
Shelf‑stable, water‑resistant packaging

Adult Dosing

Dogs ≥8 weeks, ≥2 kg: 1 mg/kg PO once every 4 weeks
Maximum single dose 56 mg (≈2.8 mg/kg) per tablet
No dose adjustment for renal or hepatic impairment

Pediatric Dosing

Puppies ≥8 weeks, ≥2 kg: same 1 mg/kg PO q4 weeks
Do not treat <8 weeks or <2 kg body weight

Indications

Treatment and monthly prevention of flea (Ctenocephalides felis) infestations
Treatment and monthly prevention of tick (Ixodes ricinus, Rhipicephalus sanguineus, Dermacentor spp.) infestations in dogs

Mechanism of Action

Selective antagonist of ligand‑gated GABA‑chloride channels in arthropod nerve cells
Causes hyperexcitation, paralysis, and death of fleas and ticks
Minimal affinity for mammalian GABA receptors

Contraindications

Known hypersensitivity to lotilaner or any excipients
Animals <8 weeks of age or <2 kg body weight
Concurrent use of other isoxazoline ectoparasiticides

Adverse Reactions

Transient vomiting or diarrhea
Mild lethargy or reduced appetite
Rare neurologic signs: tremor, ataxia, seizures
Occasional skin irritation at the oral mucosa

Drug Interactions

Potential additive CNS depression with other GABA‑modulating drugs (e.g., phenobarbital)
P‑glycoprotein inhibitors may increase systemic exposure (e.g., cyclosporine)
No clinically relevant interaction with common heartworm preventives (e.g., ivermectin)
Avoid co‑administration with other isoxazoline class products

Curated Content: Needs Vetting Before Put to Clinical Use